Get 40% Off
🤯 Perficient is up a mind-blowing 53%. Our ProPicks AI saw the buying opportunity in March.Read full update

Danone sends 1.3 million cans of Aptamil baby formula to U.S. to address shortage

Published 07/27/2022, 08:08 AM
Updated 07/27/2022, 12:47 PM
© Reuters. FILE PHOTO: French food group Danone logo is seen at the company headquarters in Rueil-Malmaison near Paris, France, February 20, 2022. REUTERS/Gonzalo Fuentes/File Photo

By Jessica DiNapoli and Richa Naidu

NEW YORK/LONDON (Reuters) -French consumer goods company Danone's North America unit said on Wednesday it had shipped more than 750,000 cans of its flagship Aptamil baby formula to the United States from Europe as a nationwide shortage persists, with another 550,000 cans on the way.

While Aptamil is little known in the United States, it is a major brand in Europe, where Danone is a dominant force in the market. The move to introduce Aptamil to American parents could give Danone, a relatively small U.S. player, the opportunity to grab market share from leaders Reckitt Benckiser and Abbott Laboratories (NYSE:ABT).

The additional 550,000 Aptamil cans that are en route from New Zealand will likely be available in August, while the initial shipments are already on shelves and online at Walgreens, Safeway and some other stores.

Danone also said it had imported more than 500,000 cans of Neocate, a specialized medical baby formula.

Abbott recalled dozens of brands of baby formula in February, sparking one of the biggest food shortages in recent American history. Since then, the U.S. government and Food and Drug Administration have made it easier for manufacturers to get shipments into the country, and appealed to companies such as Nestle and Reckitt to step up production.

In-stock rates of infant formula remain far below normal levels, at about 70% for the week ended July 24, according to data from research firm IRI. In-stock rates have remained around 70% since the end of June, according to IRI.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.